Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,[1] which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.[2]
| Combination of | |
|---|---|
| Chlorproguanil | Antimalarial drug |
| Dapsone | Antibiotic |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
References
edit- ^ Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". The Lancet. Infectious Diseases. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.
- ^ Luzzatto L (August 2010). "The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics". Lancet. 376 (9742): 739–41. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264. S2CID 34866078.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |